The pharmaceutical industry, a still embryonic sector in Africa

The pharmaceutical industry, a still embryonic sector in Africa

The pharmaceutical industry, a still embryonic sector in Africa

Published in :

Abidjan hosted the Africa Health Expo forum from December 1 to 3, dedicated to the health ecosystem in Africa. The opportunity to take stock of the pharmaceutical industry that is still struggling to develop on the continent.

With our correspondent in Abidjan, marina jeanin

Africa only produces 3% of the drugs it consumes. East hyperaddiction reminded governments during the COVID-19 pandemic. For Dr. Jean-Marc Bouchez, president of the Association of Francophone Sub-Saharan African Pharmaceutical Manufacturers, it is above all a problem of industrialization. ” There have been some production experiments, there are still some labs in development.he explains. But they are, most of the time, focused on a national market, while in order to make a real productive unit profitable, it is more necessary to talk about regional development. »

Producing antimalarials for Africa in Africa »

Jean-Marc Bouchez is also CEO of Tridem Pharma, which belongs to the Chinese healthcare giant Fosun and wants to remedy this situation. The group announced last March the construction of a production unit in Grand-Bassam, in Ivory Coast. ” It is a project that must be carried out over ten years.explains Jean-Marc Bouchez. In total, it is an investment, between the distribution center and the production unit, of 75 million euros. »

Tridem Pharma wants to transfer part of Fosun’s production from China to Côte d’Ivoire. ” A transfer of skills “, according to Jean-Marc Bouchez who details:” We are the world’s largest producer of antimalarials. So the priority will be to produce antimalarials for Africa, in Africa. Ultimately, the group is aiming for a workforce of 800 to 1,000 employees and hopes to motivate students to specialize in industrial pharmacy, where they are still in short supply.

► To listen also: How can Africa build its pharmaceutical sovereignty?

Leave a Reply

Your email address will not be published. Required fields are marked *